US2017073403A1PendingUtilityA1

Cgrp antibodies

49
Assignee: LILLY CO ELIPriority: Jun 10, 2010Filed: Nov 2, 2016Published: Mar 16, 2017
Est. expiryJun 10, 2030(~3.9 yrs left)· nominal 20-yr term from priority
Inventors:Barrett AllanRobert Jan BenschopMark Geoffrey ChambersRyan James Darling
A61P 43/00A61P 25/04A61P 25/06A61P 29/00A61P 19/02C07K 16/26C07K 2317/24C07K 2317/565C07K 2317/92C07K 2317/76C07K 2317/14C07K 2317/56A61K 2039/505A61K 2039/54C07K 16/18A61K 39/00A61K 39/395C07K 14/57563C07K 14/57545C07K 14/57527C07K 16/00
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 - 26 . (canceled) 
     
     
         27 . A method of treating migraines comprising administering to a human patient in need thereof a human engineered calcitonin gene related peptide (CGRP) antibody comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein said LCVR comprises a LCDR1 amino acid sequence RASKDISKYLN (SEQ ID NO: 6), LCDR2 amino acid sequence YTSGYHS (SEQ ID NO: 7), and LCDR3 amino acid sequence QQGDALPPT (SEQ ID NO:5), and wherein the HCVR comprises a HCDR1 amino acid sequence GYTFGNYWMQ (SEQ ID NO: 12), HCDR2 amino acid sequence AIYEGTGKTVYIQKFAD (SEQ ID NO: 16), and HCDR3 amino acid sequence LSDYVSGFGY (SEQ ID NO: 39). 
     
     
         28 . The method according to claim  1 , wherein the human engineered CGRP antibody is in a pharmaceutical composition.

Join the waitlist — get patent alerts

Track US2017073403A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.